Lydia Scarfò, MD

Lydia Scarfò, MD, discusses early safety findings with the BTK degrader BGB-16673 in R/R CLL/SLL

Lydia Scarfò, MD, discusses future research directions for BGB-16673 in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Lydia Scarfò, MD, presented updated phase 1 data from the CaDAnCe-101 study showing that BGB-16673, a novel BTK degrader, demonstrated a manageable safety profile and durable responses in heavily pretreated patients with R/R CLL/SLL, including those with prior BTKi exposure and high-risk mutations.

Lydia Scarfò, MD, explains the rationale for evaluating the BTK degrader BGB-16673 for patients with relapsed/refractory CLL.

Lydia Scarfò, MD, discusses long-term data with BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.